Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

The process of introducing a new medication to the market, starting from initial development to the final launch, is both time-intensive and heavily regulated, often spanning over a decade or more. Achieving success in this endeavor hinges on the timely availability of precise analytical data, which is essential for making informed decisions during the early stages of development and reducing the likelihood of setbacks later on. Modern drug development primarily follows a systematic approach, with the crucial first step usually being the identification of a biological target to concentrate efforts on. This target identification demands a comprehensive understanding of the characteristics of the candidates, enabling swift and reliable identification of the most promising options. After establishing a biological target, the next significant hurdle is identifying the most advantageous lead molecules, which entails discovering potential drug candidates—these may include small organic compounds or biological constructs with therapeutic capabilities. Thus, the entire journey from concept to market is a complex interplay of scientific insight and strategic decision-making.

Description

The foundational aspect of our immunotherapy approach lies in our comprehension of antigens and neoantigens, particularly in identifying which variations will be transcribed, translated, processed, and subsequently displayed on the surface of cells via Human leukocyte antigen (HLA) molecules, thus making them recognizable to T cells. We achieve this by employing Gritstone EDGETM, a unique platform powered by machine learning. Creating cancer immunotherapies that incorporate tumor-specific neoantigens proves challenging, mainly because tumors consist of numerous mutations, yet only a fraction of these lead to genuine tumor-specific neoantigens. To tackle this complexity, we have developed EDGE's cutting-edge integrated neural network model, trained with millions of data points gathered from a diverse range of tumor and normal tissue samples across various patient ancestries. This extensive training allows us to enhance the accuracy of neoantigen identification and improve the effectiveness of our immunotherapy strategies.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Bruker

Founded

1960

Country

United States

Website

www.bruker.com/en/applications/pharma/drug-discovery.html

Vendor Details

Company Name

Gritstone bio

Founded

2015

Country

United States

Website

gritstonebio.com/scientific-platform/

Product Features

Product Features

Alternatives

Alternatives

MIStar Reviews

MIStar

Apollo Medical Imaging Technology
SILCS Reviews

SILCS

SilcsBio
MIRIO Reviews

MIRIO

DEEPLINK MEDICAL